DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

Arms / Cohorts

Part 1, Group 1:Patients with Normal Hepatic Function

Accepting patients

Part 1, Group 2:Patients with Moderate Hepatic Impairment

Accepting patients

Part 2, Group 3:Patients with Severe Hepatic Impairment

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.